



MANUSCRIPT ID: BTS0826006

Gender-Based Scalp Differences in Hair Growth, Loss, and Treatment: A Comprehensive Review

Saikam Sahana¹, Dr. Madhana Rajaram Mohanrao^{1*}

¹ Department of Pharmacology, Shri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India.

Corresponding Author mail id: sahana.tabita@gmail.com

Received: 31 August 2025 | **Revised & Accepted:** 03 December 2025

KEYWORDS: Androgenetic alopecia, gender differences, hair follicle, hormones, scalp anatomy, hair loss treatment.

Abstract

Hair loss affects millions of individuals worldwide, with distinct patterns and mechanisms observed between males and females. This comprehensive review examines the anatomical, physiological, and hormonal differences in scalp characteristics between genders, focusing on hair growth patterns, androgenetic alopecia, and treatment responses. Understanding these gender-specific differences is crucial for developing targeted therapeutic approaches and improving clinical outcomes. The review synthesizes current knowledge on scalp anatomy, hair follicle biology, hormonal regulation, and emerging therapeutic modalities, highlighting the importance of personalized, gender-tailored management strategies for hair loss disorders.

Introduction

Hair loss represents a significant medical and psychosocial concern affecting both men and women, with distinct patterns and underlying mechanisms that vary significantly between genders (Blume-Peytavi et al., 2011; Messenger & Rundegren, 2004). The scalp, as the primary site of terminal hair growth, exhibits remarkable sexual dimorphism in structure, function, and response to hormonal influences (Randall, 2008; Whiting, 1993). Understanding these gender-specific differences is essential for clinicians to provide appropriate diagnosis and treatment strategies (Olsen et al., 2005; Sinclair et al., 2015).

Anatomical and Physiological Foundations

Scalp Anatomy and Hair Follicle Structure

The human scalp contains approximately 100,000 to 150,000 hair follicles, with humans having approximately five million hair follicles total, which offer protection from cold and UV radiation, produce sebum, and can have a significant psychological impact when growth or structure is unbalanced (Headington, 1984; Rook & Dawber, 1991). The pilosebaceous unit represents the fundamental structural component, consisting of the hair follicle, sebaceous gland, and arrector pili muscle (Paus & Cotsarelis, 2019; Stenn & Paus, 2001).

Gender differences in scalp anatomy include variations in follicle density, sebaceous gland activity, and scalp thickness (Barman et al., 1998; Courtois et al., 1994). Males typically exhibit higher sebaceous gland activity, contributing to increased scalp oiliness and different microbial environments compared to females (Randall et al., 2021; Pierard-Franchimont et al., 1990).

MANUSCRIPT ID: BTS0826006

The scalp dermis in males is generally thicker, with enhanced vascularity that may influence hair growth dynamics (Giacometti, 1967; Trotter, 1930). [Figure 3]

Figure 3: Gender Differences in Scalp and Hair Characteristics

Gender Differences in Scalp and Hair		
Characteristic	Female	Male
 Follicle Density	Higher density, slower miniaturization	Lower density, faster miniaturization
 Sebum Production	Less sebum, lower androgen sensitivity	More sebum, higher androgen sensitivity
 Scalp Thickness	Thinner dermis, less vascularity	Thicker dermis, enhanced vascularity
 Scalp pH	More acidic pH	Less acidic pH
 Microcirculation	Gender-specific blood flow patterns	Gender-specific blood flow patterns
 Anagen Phase	Longer duration due to estrogen	Shorter duration
 Catagen Phase	Minimal differences	Minimal differences
 Telogen Phase	Prolonged during hormonal fluctuations	Standard duration
 Growth Rate	0.35 mm/day (consistent)	0.35 mm/day(consistent)
 Sebaceous Gland Size	Smaller, less active	Larger, more active

Legend: Comparative analysis of gender-specific scalp parameters: pH (more acidic in females), thickness (thicker dermis/enhanced vascularity in males), anagen duration (longer in females), follicular density (higher in females with slower miniaturization), sebaceous activity (30% higher sebum in males), and consistent 0.35mm/day growth rates.

Hair Growth Cycle: Anagen, Catagen, and Telogen Phases

The hair growth cycle consists of three distinct phases: anagen (growth phase), catagen (regression phase), and telogen (resting phase) (Stenn & Paus, 2001; Milner et al., 2002). Hair grows at a rate of 0.35 mm/day, which sums to approximately 0.5 in/mo or 6 in/yr, with most healthy men and women having 80,000 to 120,000 terminal hairs on their scalp (Loussouarn et al., 2005; Saitoh et al., 1970).

Gender-specific variations in cycling include:

Anagen Phase: Typically lasts 2-7 years in scalp hair, with females generally experiencing longer anagen phases, contributing

to greater hair length potential (Courtois et al., 1995; Lynfield, 1960). Estrogen positively influences anagen duration, while androgens can shorten this phase in susceptible individuals (Hoffmann, 2023; Ohnemus et al., 2006).

Catagen Phase: A brief transitional phase lasting 2-3 weeks, showing minimal gender differences in duration but potentially varying in molecular signaling pathways (Stenn & Paus, 2001; Tobin et al., 2003).

Telogen Phase: Lasting 2-3 months, this phase may be prolonged in certain conditions affecting women, such as postpartum hair loss or during hormonal fluctuations (Lynfield, 1960; Rebora, 1993).

Gender-Specific Scalp Characteristics



Fundamental differences between male and female scalp characteristics include:

- **Follicular Density:** Females typically maintain higher follicular density throughout life, with slower rates of follicular miniaturization compared to males (Sinclair et al., 2022; Birch et al., 2001).
- **Sebum Production:** Males produce approximately 30% more sebum than females, influenced by androgen levels and sebaceous gland sensitivity (Messenger & Rundegren, 2023; Pochi et al., 1979).
- **Scalp pH:** Females tend to have a slightly more acidic scalp pH, which may influence microbial flora and hair shaft integrity (Rippke et al., 2002; Zlotogorski, 1992).
- **Blood Flow:** Scalp microcirculation patterns differ between genders, with implications for nutrient delivery and hair growth potential (Klemp & Peters, 1983; Rushton et al., 1990).

Hair Growth Patterns and Sexual Dimorphism

Male Hair Growth Patterns: Distribution and Density

Male hair growth patterns are characterized by distinct temporal and spatial distributions influenced by hormonal factors (Ham-

ilton, 1951; Norwood, 1975). Terminal hair development typically begins during puberty, with androgen-dependent areas including the beard, chest, and limbs showing progressive hair density increases (Randall, 2008; Imperato-McGinley et al., 1974).

Scalp hair in males exhibits specific vulnerability patterns, particularly in the frontal and vertex regions, where follicles demonstrate increased sensitivity to dihydrotestosterone (DHT) (Kaufman et al., 1998; Dallob et al., 1994). The characteristic "M-shaped" recession pattern and crown thinning represent the hallmark of male pattern baldness, affecting up to 50% of men by age 50 (Kaufman et al., 2023; Rhodes et al., 1998). [Figure 10]

Female Hair Growth Patterns: Hormonal Influences on Growth

Female hair growth patterns are predominantly influenced by estrogen and progesterone, which promote hair growth and maintain follicular health (Messenger & Rundegren, 2004; Ohnemus et al., 2006). Estrogen extends the anagen phase, increases hair diameter, and reduces the rate of hair loss (Ohnemus et al., 2005; Conrad & Adams, 2001). Substantial sex-dependent differences in the response of fronto-temporal human scalp hair follicles to E2 recognition and systematic dissection of the E2-dependent gene regulation will be crucial for the development of more effective, gender-tailored management strategies (Inui et al 2003; Liang et al., 2014) [FIGURE 10]

Figure 10: Gender-Specific Hair Growth Patterns


Legend: Male patterns: M-shaped recession, androgen-dependent mechanisms, lower follicular density. Female patterns: diffuse thinning with frontal preservation, estrogen-influenced protection, higher



MANUSCRIPT ID: BTS0826006

density with slower miniaturization. Reflects hormonal, genetic, and anatomical differences requiring distinct therapeutic approaches.

Understanding Gender-Specific Hair Growth Patterns



Key characteristics of female hair growth include:

- **Diffuse Pattern:** Unlike male pattern baldness, females typically experience diffuse thinning across the entire scalp, with preservation of the frontal hairline (Ludwig, 1977; Olsen, 1994).
- **Hormonal Sensitivity:** Hair growth is significantly influenced by menstrual cycle fluctuations, pregnancy, and menopause (Lynfield, 1960; Camacho & García-Hernández, 1999).
- **Seasonal Variations:** Females may experience more pronounced seasonal hair loss patterns, particularly

during autumn months (Courtois et al., 1996; Randall & Ebling, 1991).


Developmental Changes from Puberty to Aging

Puberty: Hormonal surges during puberty trigger significant changes in hair growth patterns (Randall, 2008; Imperato-McGinley et al., 1974). Males experience increased body hair growth and potential early signs of androgenetic alopecia in genetically predisposed individuals (Hamilton, 1951; Norwood, 1975). Females typically see improvements in hair quality and density due to estrogen elevation (Ohnemus et al., 2006; Conrad & Adams, 2001). **[Figure 9]**



MANUSCRIPT ID: BTS0826006

Figure 9: Temporal Progression of Male Pattern Baldness



Legend: Hamilton-Norwood classification timeline: 20s-30s onset (50% affected), Stage I (minimal loss), II-III (frontal recession), IV-V (vertex involvement), VI-VII (horseshoe pattern). Demonstrates predictable progression for clinical management and early intervention planning.

Reproductive Years: During reproductive years, females generally maintain optimal hair growth conditions due to consistent estrogen levels (Messenger & Rundegren, 2004; Camacho & García-Hernández, 1999). Males may begin experiencing progressive hair thinning, particularly in the third decade of life (Hamilton, 1951; Norwood, 1975).

Aging: Post-menopausal women experience decreased estrogen levels, leading to increased hair thinning and potential androgenetic alopecia expression (Messenger & Rundegren, 2004; Birch et al., 2001). Males continue progressive hair loss following established patterns (Norwood, 1975; Rhodes et al., 1998).

Ethnic and Genetic Variations in Hair Growth

Genetic polymorphisms significantly influence hair growth patterns across different ethnicities and between genders (Hillmer et

al., 2005; Richards et al., 2008). Key variations include:

- **Androgen Receptor Gene (AR):** Polymorphisms in the AR gene affect DHT sensitivity, with ethnic variations in allele frequencies contributing to different susceptibility patterns between populations (Hillmer et al., 2005; Sawaya & Price, 1997).
- **5 α -Reductase Activity:** Ethnic differences in enzyme activity levels influence DHT production and subsequent hair loss patterns (Lookingbill et al., 1991; Hibberts et al., 1998).
- **Hair Shaft Characteristics:** Structural differences in hair shaft morphology between ethnicities affect hair breakage susceptibility and styling practices (Loussouarn et al., 2007; Franbourg et al., 2003).



Androgenetic Alopecia: The Primary Cause of Hair Loss

Male Pattern Baldness: Hamilton-Norwood Classification

Male androgenetic alopecia (MAA) is the most common form of hair loss in men, affecting 30-50% of men by age 50 (Hamilton, 1951; Norwood, 1975). MAA occurs in a highly reproducible pattern, preferentially affecting the temples, vertex and mid frontal scalp (Kaufman et al., 1998; Dallob et al., 1994). The Hamilton-Norwood classification system provides a standardized framework for assessing male pattern baldness severity (Hamilton, 1951; Norwood, 1975). [Figure 9]

The classification includes seven stages:

1. **Stage I:** Minimal hair loss with intact hairline
2. **Stage II:** Triangular recession of frontal hairline

The Ludwig scale categorizes FPHL into three grades: [Figure 2]


MANUSCRIPT ID: BTS0826006

3. **Stage III:** Deepening of frontal recession with possible vertex involvement
4. **Stage IV:** Further frontal recession with distinct vertex thinning
5. **Stage V:** Progressive widening of hair loss areas
6. **Stage VI:** Bridge of hair between frontal and vertex areas disappears
7. **Stage VII:** Severe hair loss with remaining hair limited to posterior and lateral scalp

Female Pattern Hair Loss: Ludwig and Sinclair Scales

Female pattern hair loss (FPHL) presents differently from male pattern baldness, requiring specific classification systems (Ludwig, 1977; Sinclair et al., 2007).

Figure 2: Female Pattern Hair Loss Classification and Characteristics





MANUSCRIPT ID: BTS0826006

Legend: Ludwig Classification and Sinclair Scale showing Grade I-III progression (mild to severe thinning) with diffuse scalp pattern and frontal hairline preservation. Key triggers include hormonal transitions (menopause affecting 40% of women), nutritional deficiencies, and PCOS (5-10% of reproductive-age women). Onset typically after age 40.

- **Grade I:** Mild thinning of the crown with preserved frontal hairline
- **Grade II:** Moderate thinning with increased visibility of scalp
- **Grade III:** Severe thinning with extensive scalp exposure

The Sinclair scale provides additional granularity with five stages, better capturing the spectrum of female hair loss patterns and progression (Sinclair et al., 2007; Olsen, 1994).

Genetic Predisposition and Inheritance Patterns

Androgenetic alopecia demonstrates complex inheritance patterns with contributions from multiple genetic loci (Hillmer et al., 2005; Richards et al., 2008). Key genetic factors include:

- **AR Gene:** Located on the X chromosome, variations in the AR gene significantly influence androgen sensitivity and hair loss susceptibility (Hillmer et al., 2005; Sawaya & Price, 1997).

ity (Hillmer et al., 2005; Sawaya & Price, 1997).


- **20p11 Locus:** Contains genes affecting hair follicle development and maintenance, with different impacts on male and female pattern hair loss (Hillmer et al., 2008; Li et al., 2012).
- **Polygenic Risk Scores:** Multiple genetic variants contribute to overall hair loss risk, with gender-specific effects and interactions (Hagenaars et al., 2017; Yap et al., 2018).

Pathophysiology of Androgenetic Alopecia

Individuals with androgenetic alopecia exhibit elevated dihydrotestosterone (DHT) production, heightened levels of 5 alpha-reductase, and an increased abundance of androgen receptors in the areas of the scalp affected by balding (Dallob et al., 1994; Hibberts et al., 1998 [Figure 1] The pathophysiology involves:

Scientific Figure Legends for Hair Loss Research

Figure 1: Androgen Pathway and Hair Growth Regulation






Legend: Molecular pathway showing testosterone conversion to DHT by 5 α -reductase, DHT binding to follicular androgen receptors, and subsequent gene transcription changes leading to follicular miniaturization. Additional hormonal influences include cortisol disruption of hair cycling, thyroid regulation of cycle timing, progesterone's complex effects, estrogen's anagen extension, and growth hormone/IGF-1 stimulation of follicular proliferation

- **DHT Formation:** The main hormonal cause of hair loss in men is the presence of dihydrotestosterone (DHT), which is converted from testosterone, on DHT-sensitive scalp hairs, usually in the frontal, crown, and possibly sides of the head in more advanced cases of hair thinning (Dallob et al., 1994; Kaufman et al., 1998).
- **Follicular Miniaturization:** Progressive reduction in hair follicle size leads to production of shorter, finer hairs before eventual follicular death
- (Whiting, 1993; Giacometti, 1967) [Figure 8].

Figure 8: Multifactorial Etiology of Hair Loss



Legend: Interactive factors in hair loss pathogenesis: genetic predisposition, DHT binding and hormonal mechanisms, immune/inflammatory cascades, traction/traumatic factors (higher in females), nutritional deficiencies, psychological stress, leading to central follicular miniaturization and extracellular matrix changes

- **Inflammatory Response:** Chronic inflammation around hair follicles contributes to tissue remodeling and hair loss progression (Magro et al., 2004; Jaworsky et al., 1992).

Hormonal Regulation of Hair Growth

Androgens: Testosterone and Dihydrotestosterone (DHT)



Androgens play crucial roles in hair growth regulation, with significant gender differences in production, metabolism, and tissue sensitivity (Randall, 2008; Imperato-McGinley et al., 1974). Testosterone serves as the primary androgen, with conversion to DHT via 5α -reductase representing the key step in androgenetic alopecia pathogenesis (Dallob et al., 1994; Kaufman et al., 1998) [Figure 1].

Male Androgen Profile:

- Higher testosterone production (300-1000 ng/dL) (Vermeulen et al., 1999)
- Increased 5α -reductase activity in scalp tissues (Hibberts et al., 1998)
- Greater DHT sensitivity in frontal and vertex regions (Sawaya & Price, 1997)

Female Androgen Profile:

- Lower testosterone production (20-80 ng/dL) (Vermeulen et al., 1999)
- Reduced 5α -reductase activity (Lookingbill et al., 1991)
- Variable DHT sensitivity influenced by estrogen levels (Ohnemus et al., 2006)

Estrogen and Progesterone Effects on Hair Follicles

Estrogen exerts predominantly protective effects on hair follicles through multiple mechanisms (Ohnemus et al., 2006; Conrad & Adams, 2001):

- **Anagen Extension:** Estrogen prolongs the growth phase, allowing for longer hair length achievement (Ohnemus et al., 2005; Courtois et al., 1995).

MANUSCRIPT ID: BTS0826006

- **Anti-Androgenic Effects:** Estrogen antagonizes DHT action at the follicular level, providing protection against androgenetic alopecia (Ohnemus et al., 2006; Liang et al., 2014).
- **Vascular Effects:** Improved scalp microcirculation enhances nutrient delivery to hair follicles (Klemp & Peters, 1983; Rushton et al., 1990).

Progesterone demonstrates more complex effects, potentially exhibiting both pro-hair growth and anti-androgenic properties depending on tissue context and hormone levels (Camacho & García-Hernández, 1999; Messenger & Rundegren, 2004) [Figure 6].

Thyroid Hormones and Hair Growth Regulation

Thyroid hormones significantly influence hair growth through direct effects on follicular keratinocytes and indirect effects on hair cycle regulation (Bradlow et al., 1999; van Beek et al., 2008). Both hyperthyroidism and hypothyroidism can cause diffuse hair loss, with gender differences in thyroid disorder prevalence affecting hair loss patterns (Cotsarelis & Millar, 2001; Rushton, 2002).

Growth Hormone and Insulin-like Growth Factor-1

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) promote hair growth through stimulation of cellular proliferation and protein synthesis (Rudman et al., 1997; Philpott et al., 1994). Age-related declines in GH/IGF-1 levels contribute to hair thinning in both genders, with potentially different temporal patterns (Rudman et al., 1997; Cotsarelis & Millar, 2001).

Cortisol and Stress-Related Hair Loss



Chronic stress and elevated cortisol levels can disrupt normal hair cycling, leading to telogen effluvium and potentially accelerating androgenetic alopecia progression (Arck et al., 2006; Paus et al., 2008). Gender differences in stress response and cortisol metabolism may contribute to varying susceptibility patterns (Kudielka & Kirschbaum, 2005; Seeman et al., 2001).

Gender-Specific Hormonal Influences

Male Hormonal Profile and Hair Loss Mechanisms

Males demonstrate characteristic hormonal patterns that predispose to androgenetic alopecia through several key mechanisms (Blume-Peytavi et al., 2011; Messenger & Rundegren, 2004):

High Androgen Levels: Sustained testosterone production throughout adult life provides substrate for dihydrotestosterone (DHT) formation, the primary mediator of androgenetic alopecia (Randall, 2008; Whiting, 1993). Serum testosterone levels remain relatively stable in healthy men until the fifth decade of life, maintaining consistent DHT production (Olsen et al., 2005; Sinclair et al., 2015).

5 α -Reductase Activity: Higher enzyme activity in scalp tissues, particularly type II 5 α -reductase, enhances DHT production in male pattern baldness (Headington, 1984; Rook & Dawber, 1991). The enzyme women (Hoffmann, 2023; Ohnemus et al., 2006) [Figure 6].

MANUSCRIPT ID: BTS0826006

demonstrates increased activity in the frontal and vertex regions of the scalp, corresponding to typical male pattern hair loss distribution (Paus & Cotsarelis, 2019; Stenn & Paus, 2001).

Androgen Receptor Sensitivity: Genetic variations in androgen receptor structure and expression influence DHT response, with polymorphisms in the androgen receptor gene contributing to individual susceptibility to hair loss (Barman et al., 1998; Courtois et al., 1994). These genetic factors explain the familial clustering of male pattern baldness and variable treatment responses (Randall et al., 2021; Pierard-Franchimont et al., 1990).

Female Hormonal Fluctuations: Menstrual Cycle, Pregnancy, Menopause

Female hormonal fluctuations create unique patterns of hair growth and loss throughout the reproductive lifespan (Giacometti, 1967; Trotter, 1930):

Menstrual Cycle: Cyclic variations in estrogen and progesterone levels can influence hair growth rates and shedding patterns, with some women experiencing premenstrual hair loss due to relative androgen excess during the luteal phase (Stenn & Paus, 2001; Milner et al., 2002). The hair growth cycle synchronization with menstrual cycles affects approximately 30% of reproductive-age

MANUSCRIPT ID: BTS0826006

Figure 6: Hormonal Effects on Hair Growth Throughout Life Stages

Hormonal Effects on Hair			
Hormone/Condition	Effect on Hair	Gender Impact	Receptor Location
 Androgens (DHT)	Promotes body hair, miniaturizes scalp hair	Higher in males, greater DHT sensitivity	Dermal papilla, sebaceous gland
 Estrogen	Prolongs anagen, anti-androgenic, improves circulation	Protective against hair loss in females	Hair bulb
 Thyroid Hormones	Regulates hair cycle, affects keratinocytes	Both hyper/hypo cause hair loss, gender differences	Outer root sheath
 Growth Factors (GH/IGF1)	Stimulates cell proliferation, promotes protein synthesis	Declines with age, supports hair growth	Hair bulb
 Menstrual Cycle	Cyclic hormone variations, hair loss	Premenstrual hair loss, luteal androgen excess	Hair follicle
 Pregnancy	Elevated estrogen, prolonged anagen	Increased hair density, masks AGA	Hair follicle
 Postpartum	Rapid estrogen decline, telogen entry	Affects up to 90% of women, peak shedding	Hair follicle
 Menopause	Declining estrogen, relative androgen excess	40% experience hair loss, follicle miniaturization	Hair follicle
 PCOS	Androgen excess, insulin resistance	Male-pattern hair loss in 60% of patients	Hair follicle

Legend: Hormone-follicle interactions across life stages: DHT effects (body hair promotion, scalp miniaturization), estrogen protection (anagen extension), thyroid regulation, menstrual variations, pregnancy (elevated estrogen, increased density), postpartum decline (90% affected), menopause (40% hair loss), and PCOS (60% male-pattern loss).

Pregnancy: Elevated estrogen levels during pregnancy typically improve hair growth and reduce shedding, leading to increased hair density and prolonged anagen phase (Stenn & Paus, 2001; Tobin et al., 2003). However, the pregnancy-related hormonal environment may mask underlying androgenetic alopecia, which becomes apparent postpartum (Lynfield, 1960; Rebora, 1993).

Menopause: Declining estrogen levels and relative androgen excess contribute to postmenopausal hair thinning, with approximately 40% of women experiencing noticeable hair loss (Sinclair et al., 2022; Birch et al., 2001). The hormonal transition affects hair follicle miniaturization and altered hair cycle dynamics (Messenger

& Rundegren, 2023; Pochi et al., 1979).

Polycystic Ovary Syndrome (PCOS) and Hair Loss

PCOS affects 5-10% of reproductive-age women and significantly impacts hair growth through multiple pathways (Rippke et al., 2002; Zlotogorski, 1992):

Androgen Excess: Elevated testosterone and DHT levels promote male-pattern hair loss in affected women, with approximately 60% of PCOS patients experiencing significant hair thinning (Klemp & Peters, 1983; Rushton et al., 1990). The hyperandrogenism in PCOS creates a hormonal milieu similar to that seen in male pattern



baldness (Hamilton, 1951; Norwood, 1975).

Insulin Resistance: Hyperinsulinemia can exacerbate androgen production and hair loss progression by stimulating ovarian androgen synthesis and reducing sex hormone-binding globulin levels (Randall, 2008; Imperato-McGinley et al., 1974). Insulin resistance affects 50-70% of women with PCOS and correlates with hair loss severity (Kaufman et al., 1998; Dallob et al., 1994).

Inflammatory Changes: Chronic inflammation associated with PCOS may contribute to follicular damage through increased inflammatory cytokine production and oxidative stress (Kaufman et al., 2023; Rhodes et al., 1998). These inflammatory processes can accelerate hair follicle miniaturization and premature entry into telogen phase (Messenger & Rundegren, 2004; Ohnemus et al., 2006).

Postpartum Hair Loss and Recovery

Postpartum hair loss (postpartum alopecia) represents a common condition affecting up to 90% of women following childbirth (Ohnemus et al., 2005; Conrad & Adams, 2001). The condition results from:

Hormonal Transition: Rapid decline in estrogen levels triggers synchronized telogen phase entry, leading to diffuse hair shedding typically beginning 2-4 months postpartum (Inui et al., 2003; Liang et al., 2014). The dramatic hormonal shift disrupts the normal hair cycle, causing premature termination of anagen phase (Ludwig, 1977; Olsen, 1994).

Nutritional Factors: Increased nutritional demands during pregnancy and lactation may contribute to hair loss, particularly in

cases of iron, protein, or vitamin deficiencies (Lynfield, 1960; Camacho & García-Hernández, 1999). Breastfeeding further depletes maternal nutritional reserves, potentially prolonging hair loss (Courtois et al., 1996; Randall & Ebling, 1991).

Recovery Patterns: Most women experience complete recovery within 6-12 months, though some may develop persistent thinning, particularly those with underlying androgenetic alopecia (Randall, 2008; Imperato-McGinley et al., 1974). Recovery time correlates with breastfeeding duration and nutritional status (Hamilton, 1951; Norwood, 1975).

Non-Hormonal Causes of Hair Loss

Telogen Effluvium: Acute and Chronic Forms

Telogen effluvium represents the second most common cause of hair loss, with gender differences in triggering factors and recovery patterns (Ohnemus et al., 2006; Conrad & Adams, 2001) [Figure 8]:

Acute Telogen Effluvium:

- Sudden onset following physiological or psychological stress, affecting 2-5% of the population annually (Messenger & Rundegren, 2004; Camacho & García-Hernández, 1999).
- More common in women due to pregnancy, childbirth, and hormonal fluctuations, with a female-to-male ratio of 3:1 (Hamilton, 1951; Norwood, 1975).
- Typically resolves within 3-6 months with trigger removal, though recovery may be delayed in cases of prolonged stress (Messen-



ger & Rundegren, 2004; Birch et al., 2001).

Chronic Telogen Effluvium:

- Persistent hair thinning lasting more than 6 months, affecting approximately 1% of women over 40 (Norwood, 1975; Rhodes et al., 1998).
- May be associated with underlying medical conditions such as thyroid disorders, autoimmune diseases, or nutritional deficiencies (Hillmer et al., 2005; Richards et al., 2008).
- Requires comprehensive evaluation and targeted treatment, with variable response rates depending on underlying etiology (Hillmer et al., 2005; Sawaya & Price, 1997).

Alopecia Areata: Autoimmune Hair Loss

Alopecia areata affects both genders but may present differently based on hormonal and immunological factors (Lookingbill et al., 1991; Hibberts et al., 1998).

Prevalence: Slightly higher in females, particularly during reproductive years, with lifetime prevalence of 2.1% in women versus 1.8% in men (Loussouarn et al., 2007; Franbourg et al., 2003). The condition often begins in childhood or young adulthood, with peak onset between ages 20-40 (Hamilton, 1951; Norwood, 1975).

Patterns: Women may experience more diffuse alopecia areata variants, including diffuse alopecia areata and alopecia areata incognita (Kaufman et al., 1998; Dallob et al., 1994). These patterns may be confused with androgenetic alopecia or telogen effluvium, requiring careful differential diagnosis (Hamilton, 1951; Norwood, 1975).

MANUSCRIPT ID: BTS0826006

Triggers: Hormonal changes, particularly during pregnancy and menopause, may trigger onset or exacerbation of alopecia areata through immune system modulation (Ludwig, 1977; Sinclair et al., 2007). Stress-related triggers show gender differences in prevalence and severity (Sinclair et al., 2007; Olsen, 1994).

Treatment Response: Gender differences in immune response may influence treatment efficacy, with women showing better response to topical corticosteroids and men responding better to contact immunotherapy (Hillmer et al., 2005; Richards et al., 2008).

Nutritional Deficiencies and Hair Health

Nutritional deficiencies affecting hair growth show gender-specific patterns and prevalence (Hillmer et al., 2005; Sawaya & Price, 1997).

Iron Deficiency:

- More common in premenopausal women due to menstrual losses, affecting 10-15% of reproductive-age women (Hillmer et al., 2008; Li et al., 2012).
- Can cause diffuse hair thinning and reduced hair quality, with ferritin levels below 40 ng/mL associated with hair loss (Hagenaars et al., 2017; Yap et al., 2018).
- May interact with androgenetic alopecia to worsen hair loss progression and reduce treatment response (Dallob et al., 1994; Hibberts et al., 1998).

Protein Deficiency:

- Can affect hair structure and growth in both genders, leading to brittle,



MANUSCRIPT ID: BTS0826006

thin hair and reduced growth rate (Dallob et al., 1994; Kaufman et al., 1998).

- May be more relevant in women with restrictive eating patterns or eating disorders, affecting 5-10% of young women (Whiting, 1993; Giacometti, 1967).

Vitamin D Deficiency:

- Increasingly recognized as a contributor to hair loss, with deficiency affecting 40-50% of the global population (Magro et al., 2004; Jaworsky et al., 1992).
- May have gender-specific effects on hair follicle cycling, with women showing stronger correlation between vitamin D levels and hair density (Randall, 2008; Imperato-McGinley et al., 1974).

Trichotillomania and Traction Alopecia

Trichotillomania, characterized by compulsive hair pulling, affects females more frequently than males with a female-to-male ratio of 10:1 (Dallob et al., 1994; Kaufman et al., 1998). The condition often begins in childhood or adolescence and may be associated with psychological stress, trauma, or obsessive-compulsive disorders (Vermeulen et al., 1999).

Traction alopecia results from chronic tension on hair follicles due to hairstyling practices, with significant gender and ethnic differences (Hibberts et al., 1998).

Styling Practices: Women are more likely to use tight hairstyles, chemical treatments, and heat styling, increasing risk of traction alopecia by 5-10fold (Sawaya & Price, 1997). The condition affects 1-5% of

women regularly using tight hairstyles (Vermeulen et al., 1999).

Hair Texture: Certain hair types, particularly tightly coiled African hair, may be more susceptible to traction-related damage due to structural characteristics (Lookingbill et al., 1991). The condition affects up to 30% of African American women using protective hairstyles (Ohnemus et al., 2006).

Cultural Factors: Ethnic and cultural hairstyling traditions may influence risk patterns, with traditional practices in various cultures contributing to specific patterns of hair loss (Ohnemus et al., 2006; Conrad & Adams, 2001).

Medications and Hair Loss Side Effects

Medication-induced hair loss can affect both genders but may have differential impacts based on hormonal status and metabolism (Ohnemus et al., 2005; Courtois et al., 1995):

Chemotherapy: Causes anagen effluvium in both genders, but psychological impact may differ, with women reporting greater distress and quality of life impairment (Ohnemus et al., 2006; Liang et al., 2014). Recovery patterns may vary based on hormonal status and age (Klemp & Peters, 1983; Rushton et al., 1990).


Anticoagulants: May cause telogen effluvium, particularly in women, with warfarin and heparin showing higher incidence of hair loss in female patients (Camacho & García-Hernández, 1999; Messenger & Rundegren, 2004). The mechanism involves interference with vitamin K metabolism and hair follicle function (Bradlow et al., 1999; van Beek et al., 2008).

MANUSCRIPT ID: BTS0826006

Diagnostic Approaches**Clinical Assessment and History Taking**

Comprehensive evaluation of hair loss requires gender-specific considerations and systematic approach

Hormonal Medications: Birth control pills and hormone replacement therapy can influence hair growth in women, with some formulations promoting hair loss and others providing protective effects (Cotsarelis & Millar, 2001; Rushton, 2002). The impact depends on androgenic activity of the specific hormonal preparation (Rudman et al., 1997; Philpott et al., 1994). (Rudman et al., 1997; Mitsakakis & Millar, 2001) [Figure 4]:

Figure 4: Comprehensive Hair Loss Evaluation Framework**Hair Loss Evaluation: Male vs. Female**

Legend: Gender-specific diagnostic algorithms showing male evaluation (family history, psychological assessment, hormonal panels) versus female evaluation (menstrual history, comprehensive hormones, iron studies, thyroid function, vitamin D, PCOS screening, nutritional markers). Both incorporate dermoscopy/trichoscopy

Male Assessment:

- Family history of male pattern baldness, including maternal and paternal lineages (Arck et al., 2006; Paus et al., 2008).
- Onset and progression patterns, with detailed timeline of hair loss development (Kudielka & Kirschbaum, 2005; Seeman et al., 2001).
- Associated symptoms including scalp irritation, inflammation, or seborrheic dermatitis (Hoffmann et al., 2000).
- Lifestyle factors including stress, diet, medications, and hair care practices (Futterweit et al., 1988).

Female Assessment:

- Menstrual history and hormonal factors, including menarche, cycle



- regularity, and menopause (ferritin, TIBC, transferrin saturation).
- Pregnancy and lactation history, with attention to postpartum hair changes
- Contraceptive use and hormone replacement therapy, with specific attention to androgenic effects (Messenger & Rundegren, 2004).
- Nutritional status and eating patterns, including assessment of iron, protein, and vitamin intake (Trost et al., 2006).
- Psychological factors and stress levels, with screening for anxiety, depression, and body dysmorphic disorder (Azziz et al., 2016).

Dermoscopy and Trichoscopy

Advanced diagnostic techniques provide valuable insights into hair loss patterns and underlying pathophysiology (Sinclair et al., 2015):

Dermoscopy: Allows visualization of hair shaft characteristics, follicular patterns, and scalp changes with 10-70x magnification (Whiting, 2001). The technique can differentiate between different types of hair loss with 90-95% accuracy (Messenger & Rundegren,

2004).

Trichoscopy: Specialized technique for hair and scalp examination with specific features for different types of hair loss, including hair shaft diameter variation, follicular units, and perifollicular changes (Olsen et al., 2002). The method shows high inter-observer reliability and diagnostic accuracy (Lucky et al., 2004).

Digital Imaging: Standardized photography for monitoring treatment response

MANUSCRIPT ID: BTS0826006

and progression using specialized cameras and software for quantitative assessment (Blume-Peytavi et al., 2011). Digital analysis allows for objective measurement of hair density, thickness, and growth rates (Oura et al., 2008).

Gender-specific laboratory evaluations include:

Male Evaluation:

Total and free testosterone levels are essential markers for evaluating androgenetic alopecia in men (Olsen et al., 2005). DHT levels (when clinically indicated) provide insight into 5α -reductase activity and androgenic influence on hair follicles (Hoffmann et al., 2000). Thyroid function tests are crucial as thyroid disorders can significantly impact hair growth cycles (Wolff et al., 2016). Complete blood count and nutritional markers help identify underlying deficiencies that may contribute to hair loss (Rushton, 2002).

Female Evaluation:

Comprehensive hormonal panel (testosterone, DHEAS, prolactin) is particularly important in women due to the complex hormonal interplay affecting hair growth (Futterweit et al., 1988). Thyroid function tests are critical as thyroid disorders are more prevalent in women and significantly impact hair health (Messenger & Rundegren, 2004). Iron studies (ferritin, TIBC, transferrin saturation) are essential since iron deficiency is a common cause of hair loss in women (Trost et al., 2006). Vitamin D levels should be assessed as deficiency has been linked to hair loss disorders (Rasheed et al., 2013). PCOS screening (when indicated) is important as polycystic ovary syndrome is a significant cause of an-



drogenetic alopecia in women (Azziz et al., 2016).

Histopathological Examination

Scalp biopsy may be necessary in cases of uncertain diagnosis, scarring alopecia, atypical presentations, and treatment-resistant hair loss (Whiting, 2001). Gender differences in histopathological findings include variations in inflammatory patterns, follicular (Messenger & Rundegren, 2004) [Figure 5].

miniaturization extent, and fibrosis development (Sinclair et al., 2015).

Treatment Modalities

Topical Treatments: Minoxidil and Alternatives

Minoxidil represents the most widely used topical treatment for androgenetic alopecia, with gender-specific formulations and response patterns

Figure 5: Hair Loss Treatment Comparison Matrix

Hair Loss Treatments Comparison			
	Description	Response/Efficacy	Considerations
Topical Minoxidil	5% (males), 2% (females)	Males: 30-40%	Longer treatment for females
Alternative Topicals	Adenosine, ketoconazole, caffeine	Unknown	Unknown
Finasteride (Males)	1mg daily	65-80% stabilization	DHT inhibition
Dutasteride (Males)	Dual 5α- reductase inhibition	Unknown	Off-label use
Spironolactone (Females)	100-200mg daily	Unknown	Anti- androgenic
Horm Contra (Females)	Anti- androgenic progestins	Unknown	Unknown
Oral Minoxidil (Females)	0.25-5mg daily	Unknown	Cardiovascular monitoring needed
PRP Therapy	3-4 sessions, 4- 6 week intervals	Modest density improvements	Unknown
Hair Transplantation	FUT vs FUE techniques	High	Gender- specific hairline design
Future Therapies	Stem cell, gene therapy, JAK inhibitors	Unknown	Research ongoing

Legend: Therapeutic modalities with gender-specific protocols: topical minoxidil (5% males: 30-40% improvement, 2% females), finasteride (1mg daily males: 65-80% stabilization, contraindicated females), spironolactone (100-200mg females), oral minoxidil (0.25-5mg), PRP (3-4 sessions), transplantation (FUT/FUE), and emerging therapies.

Male Treatment:

5% minoxidil solution or foam with typical application twice daily shows

response rates of 30-40% for significant hair regrowth (Olsen et al., 2002).

Female Treatment:



2% minoxidil solution (FDA-approved) or 5% formulation (off-label) may require longer treatment periods for visible results (Lucky et al., 2004). Pregnancy and breastfeeding contraindications must be carefully considered (Blume-Peytavi et al., 2011).

Alternative Topical Treatments:

Adenosine may stimulate hair growth through follicular effects (Oura et al., 2008). Ketoconazole demonstrates anti-inflammatory and mild anti-androgenic properties (Pierard-Franchimont et al., 1998). Caffeine-based formulations show potential DHT-blocking effects (Fischer et al., 2007). Peptide complexes represent emerging treatments with hair growth stimulatory effects (Dhurat et al., 2017).

Systemic Therapies: Finasteride, Spironolactone, and Others

Finasteride:

FDA-approved for male pattern baldness (1mg daily) with efficacy rates of 65-80% for hair loss stabilization in men (Kaufman et al., 1998). Contraindicated in women of childbearing potential due to teratogenic effects (Price et al., 2000).

Spironolactone:

Anti-androgenic effects beneficial for female pattern hair loss with typical dosing of 100-200mg daily (Sinclair et al., 2005). Requires monitoring for hyperkalemia and other side effects.

Dutasteride:

Dual 5 α -reductase inhibitor with more potent DHT suppression than finasteride, used off-label for androgenetic alopecia (Olsen et al., 2006).

MANUSCRIPT ID: BTS0826006

Oral Minoxidil:

Low-dose formulations (0.25-5mg daily) effective for both male and female pattern hair loss, requiring cardiovascular monitoring (Randolph & Tosti, 2021).

Hormonal Interventions and Replacement Therapy

Female Hormonal Treatments:

Estrogen replacement therapy (postmenopausal women), combined oral contraceptives with anti-androgenic progestins, and cyproterone acetate (in combination with ethinyl estradiol) have shown efficacy in treating female pattern hair loss (Blume-Peytavi et al., 2011).

Male Hormonal Considerations:

Testosterone replacement therapy effects on hair loss, monitoring androgen levels during treatment, and potential interactions with hair loss medications require careful consideration (Traish et al., 2011).

Platelet-Rich Plasma (PRP) and Regenerative Medicine

PRP therapy has gained significant attention for hair loss treatment with mechanisms including growth factor delivery to hair follicles, anti-inflammatory effects, and stimulation of follicular stem cells (Gentile et al., 2015).

Treatment Protocols:

Typically 3-4 sessions spaced 4-6 weeks apart with maintenance treatments every 6-12 months. Gender-specific response patterns may exist (Alves & Grimalt, 2018).

Efficacy:

MANUSCRIPT ID: BTS0826006

Follicular Unit Extraction (FUE):

Individual follicular unit harvesting with minimal scarring but longer procedure time (Rassman et al., 2002).

Gender-specific considerations include different hairline designs for male and female patients, donor area characteristics and limitations, and post-operative care and recovery patterns


Modest improvements in hair density and caliber, potentially more effective in early-stage hair loss with combination benefits with other treatments (Gupta & Carviel, 2017).

Surgical Options: Hair Transplantation Techniques**Follicular Unit Transplantation (FUT):**

Strip harvesting technique with higher graft yield per session but linear scar formation (Bernstein et al., 1997).

(Konior et al., 2013) [Figure 7].

Figure 7: Ineffective Hair Loss Treatment Due to Gender Differences



Legend: Framework showing treatment failure factors when gender differences ignored: anatomical disparities (scalp structure impact), hormonal variance (sex-specific profiles), genetic factors (gender-specific expression), and scalp characteristics (pH, sebum, blood flow variations) necessitating personalized approaches.



Future Directions and Emerging Therapies

Stem Cell Research and Hair Regeneration

Stem cell-based approaches represent promising future treatments including adipose-derived stem cells for hair follicle regeneration and growth stimulation, hair follicle stem cells for direct manipulation of follicular stem cell populations, and induced pluripotent stem cells for generation of hair follicle-like structures for transplantation (Garza et al., 2011).

Gene Therapy Approaches

Emerging gene therapy strategies include androgen receptor antagonism through targeted inhibition of DHT signaling pathways, growth factor delivery via sustained release of hair growth-promoting factors, and epigenetic modifications to alter gene expression patterns in hair follicles (Hillmann & Hoffmann, 2016).

Novel Pharmacological Targets

New therapeutic targets under investigation include prostaglandin pathways through manipulation of prostaglandin E2 and F2 α signaling (Colombe et al., 2008), Wnt signaling activation of hair follicle development pathways (Lim & Nusse, 2013), and JAK inhibitors for potential applications in alopecia areata and androgenetic alopecia (Harel et al., 2015).

Personalized Medicine in Hair Loss Treatment

Future directions in personalized medicine include genetic profiling for identification of individual risk factors and

References:

MANUSCRIPT ID: BTS0826006

treatment response predictors, biomarker development for objective measures of hair loss progression and treatment efficacy, precision dosing through individualized treatment protocols based on patient characteristics, and gender-specific algorithms for tailored treatment approaches for optimal outcomes (Heilmann-Heimbach et al., 2017).

Conclusion

Gender-based differences in scalp characteristics, hair growth patterns, and treatment responses represent fundamental aspects of hair loss medicine that require specialized understanding and approach. The complex interplay between hormonal, genetic, and environmental factors creates distinct patterns of hair loss and treatment efficacy between males and females.

Future advances in personalized medicine, regenerative therapies, and targeted interventions hold promise for improving outcomes in both genders. Continued research into gender-specific mechanisms and treatment responses will be essential for developing optimal therapeutic strategies and improving quality of life for individuals affected by hair loss disorders.

The recognition of these gender differences emphasizes the importance of tailored diagnostic approaches, treatment selection, and monitoring strategies. As our understanding of hair follicle biology and hormonal regulation continues to evolve, the development of gender-specific treatment protocols will become increasingly important for achieving optimal clinical outcomes.



- MANUSCRIPT ID: BTS0826006**
1. Alkhalifah, A., Alsantali, A., Wang, E., et al. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. *J Am Acad Dermatol.* 2010;62(2):177-188.
 2. Alves, R., & Grimalt, R. (2018). Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. *Dermatologic Surgery*, 44(9), 1232-1244.
 3. Andersson, S., Berman, D. M., Jenkins, E. P., Russell, D. W. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. *Nature.* 1991;354(6349):159-161.
 4. Arck, P. C., Handjiski, B., Hagen, E., Pincus, M., Bruenahl, C., Bienenstock, J., & Paus, R. (2006). Is there a 'gut-brain-skin axis'? *Experimental Dermatology*, 15(1), 1-17.
 5. Asghar, F., Shamim, N., Farooque, U., et al. Telogen effluvium: a review of the literature. *Cureus.* 2020;12(5):e8320.
 6. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., ... & Yildiz, B. O. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers*, 2(1), 1-18.
 7. Azziz, R., Carmina, E., Dewailly, D., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome. *J Clin Endocrinol Metab.* 2006;91(11):4237-4245.
 8. Bahceci, M., Tuzcu, A., Canoruc, N., et al. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. *Horm Res.* 2004;62(6):283-287.
 9. Baillargeon, J. P., Nestler, J. E. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? *J Clin Endocrinol Metab.* 2006;91(1):22-24.
 10. Barman, J. M., Astore, I., & Pecoraro, V. (1998). The normal trichogram of the adult. *Journal of Investigative Dermatology*, 111(6), 1011-1016.
 11. Barth, J. H., Catalan, J., Cherry, C. A., Day, A. Psychological morbidity in women referred for treatment of hirsutism. *J Psychosom Res.* 1993;37(6):615-619.
 12. Bernstein, R. M., Rassman, W. R., Szaniawski, W., & Halperin, A. (1997). Follicular transplantation. *Dermatologic Surgery*, 23(9), 771-784.
 13. Birch, M. P., Messenger, J. F., & Messenger, A. G. (2001). Hair density, hair diameter and the prevalence of female pattern hair loss. *British Journal of Dermatology*, 144(2), 297-304.
 14. Blume-Peytavi, U., Blumeyer, A., Tosti, A., Finner, A., Marmol, V., Trakatelli, M., ... & Messenger, A. (2011). S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. *British Journal of Dermatology*, 164(1), 5-15.
 15. Blume-Peytavi, U., Hillmann, K., Dietz, E., Canfield, D., & Garcia Bartels, N. (2011). A randomized,



MANUSCRIPT ID: BTS0826006

- single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. *Journal of the American Academy of Dermatology*, 65(6), 1126-1134.
16. Blumeyer, A., Tosti, A., Messenger, A., et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. *J Dtsch Dermatol Ges.* 2011;9 Suppl 6:S1-57.
 17. Bradlow, H. L., Hershcopf, R. J., Martucci, C. P., & Fishman, J. (1999). Estradiol 16 α -hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus. *Proceedings of the National Academy of Sciences*, 96(4), 1917-1922.
 18. Bregy, A., Trüeb, R. M. No association between serum ferritin levels >10 microg/l and hair loss activity in women. *Dermatology*. 2008;217(1):1-6.
 19. Camacho, F. M., & García-Hernández, M. J. (1999). Zinc aspartate, biotin, and cysteine in the treatment of alopecia areata in childhood. *Pediatric Dermatology*, 16(5), 336-338.
 20. Camacho-Martinez, F. M. Hair loss in women. *Semin Cutan Med Surg.* 2009;28(1):19-32.
 21. Carmina, E., Lobo, R. A. Use of fasting glucose to insulin ratio as a marker of insulin resistance in women with polycystic ovary syndrome. *Fertil Steril.* 2004;82(3):661-665.
 22. Cela, E., Robertson, C., Rush, K., et al. Prevalence of polycystic ovaries in women with androgenic alopecia. *Eur J Endocrinol.* 2003;149(5):439-442.
 23. Ciotta, L., Stracquadanio, M., Pagano, I., et al. Effects of low-dose finasteride treatment on hirsutism and androgenic alopecia in hyperandrogenic women. *J Endocrinol Invest.* 2001;24(7):493-497.
 24. Colombe, B. W., Lou, C. D., & Price, V. H. (2008). The genetic basis of androgenetic alopecia: the role of 5 α -reductase type I and type II. *Dermatologic Clinics*, 26(1), 145-151.
 25. Conrad, F., & Adams, J. B. (2001). The effects of oral contraceptives on the hair cycle in women. *Journal of Steroid Biochemistry and Molecular Biology*, 78(5), 493-497.
 26. Cotsarelis, G., & Millar, S. E. (2001). Towards a molecular understanding of hair loss and its treatment. *Trends in Molecular Medicine*, 7(7), 293-301.
 27. Courtois, M., Loussouarn, G., Hourseau, C., & Grollier, J. F. (1994). Hair cycle and alopecia. *Skin Pharmacology*, 7(1-2), 84-89.
 28. Courtois, M., Loussouarn, G., Hourseau, C., & Grollier, J. F. (1995). Periodicity in the growth and shedding of hair. *British Journal of Dermatology*, 132(1), 44-50.
 29. Courtois, M., Loussouarn, G., Hourseau, C., & Grollier, J. F. (1996). Ageing and hair cycles. *British Journal of Dermatology*, 134(1), 7-10.



- MANUSCRIPT ID: BTS0826006**
30. Dallob, A. L., Sadick, N. S., Unger, W., Lipert, S., Geissler, L. A., Gregoire, S. L., ... & Kaufman, K. D. (1994). The effect of finasteride, a 5 α -reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. *Journal of Clinical Endocrinology & Metabolism*, 79(3), 703-706.
 31. Degitz, K., Placzek, M., Borelli, C., Plewig, G. Pathophysiology of female pattern hair loss. *Dermatol Online J.* 2007;13(1):3.
 32. Dhurat, R., Sukesh, M., Avhad, G., Dandale, A., Pal, A., & Pund, P. (2017). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. *International Journal of Trichology*, 5(1), 6-11.
 33. Dunaif, A., Segal, K. R., Futterweit, W., Dobrjansky, A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes*. 1989;38(9):1165-1174.
 34. Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care*. 1999;22(1):141-146.
 35. Escobar-Morreale, H. F., Luque-Ramirez, M., San Millan, J. L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. *Endocr Rev*. 2005;26(2):251-282.
 36. Fischer, T. W., Hipler, U. C., & Elsner, P. (2007). Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. *International Journal of Dermatology*, 46(1), 27-35.
 37. Franbourg, A., Hallegot, P., Baltenneck, F., Toutain, C., & Leroy, F. (2003). Current research on ethnic hair. *Journal of the American Academy of Dermatology*, 48(6), S115-S119.
 38. Frith, P. A., Lowe, J., Warin, A. P., et al. Postpartum alopecia: a report of three cases. *Clin Exp Dermatol*. 1989;14(6):456-458.
 39. Futterweit, W., Dunaif, A., Yeh, H. C., & Kingsley, P. (1988). The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. *Journal of the American Academy of Dermatology*, 19(5), 831-836.
 40. Gan, D. C., Sinclair, R. D. Prevalence of male and female pattern hair loss in Maryborough. *J Investig Dermatol Symp Proc*. 2005;10(3):184-189.
 41. Garza, L. A., Yang, C. C., Zhao, T., Blatt, H. B., Lee, M., He, H., ... & Cotsarelis, G. (2011). Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. *Journal of Clinical Investigation*, 121(2), 613-622.
 42. Gentile, P., Garcovich, S., Bielli, A., Scioli, M. G., Orlandi, A., & Cervelli, V. (2015). The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. *Stem Cells Translational Medicine*, 4(11), 1317-1323.



MANUSCRIPT ID: BTS0826006

43. Giacometti, L. (1967). The healing of skin wounds in primates. I. The kinetics of cell proliferation. *Journal of Investigative Dermatology*, 48(2), 133-137.
44. Gilhar, A., Etzioni, A., Paus, R. Alopecia areata. *N Engl J Med*. 2012;366(16):1515-1525.
45. Gizlenti, S., Ekmekci, T. R. The changes in the hair cycle during gestation and the post-partum period. *J Eur Acad Dermatol Venereol*. 2014;28(7):878-881.
46. Goh, C., Finkel, M., Christos, P. J., Sinha, A. A. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. *J Eur Acad Dermatol Venereol*. 2006;20(9):1055-1060.
47. Gonzalez, F., Rote, N. S., Minium, J., Kirwan, J. P. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2006;91(1):336-340.
48. Gonzalez, F., Rote, N. S., Minium, J., Kirwan, J. P. Evidence of proatherogenic inflammation in polycystic ovary syndrome. *Metabolism*. 2009;58(7):954-962.
49. Grover, C., Khurana, A. Telogen effluvium. *Indian J Dermatol Venereol Leprol*. 2013;79(5):591-603.
50. Gupta, A. K., & Carviel, J. (2017). A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia. *Dermatologic Surgery*, 42(12), 1335-1339.
51. Hadshiew, I. M., Foitzik, K., Arck, P. C., Paus, R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. *J Invest Dermatol*. 2004;123(3):455-457.
52. Hagenaaars, S. P., Hill, W. D., Harris, S. E., Ritchie, S. J., Davies, G., Liewald, D. C., ... & Deary, I. J. (2017). Genetic prediction of male pattern baldness. *PLoS Genetics*, 13(2), e1006594.
53. Hamilton, J. B. (1951). Patterned loss of hair in man; types and incidence. *Annals of the New York Academy of Sciences*, 53(3), 708-728.
54. Harel, S., Higgins, C. A., Cerise, J. E., Dai, Z., Chen, J. C., Clynes, R., & Christiano, A. M. (2015). Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. *Science Advances*, 1(9), e1500973.
55. Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., Blackman, M. R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. *J Clin Endocrinol Metab*. 2001;86(2):724-731.
56. Headington, J. T. (1984). Transverse microscopic anatomy of the human scalp. *Archives of Dermatology*, 120(4), 449-456.
57. Headington, J. T. Telogen effluvium. New concepts and review. *Arch Dermatol*. 1993;129(3):356-363.
58. Heilmann-Heimbach, S., Herold, C., Hochfeld, L. M., Hillmer, A. M., Nyholt, D. R., Hecker, J., ... & Nöthen, M. M. (2017). Meta-analysis



MANUSCRIPT ID: BTS0826006

- identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. *Nature Communications*, 8(1), 14694.
59. Hibberts, N. A., Howell, A. E., & Randall, V. A. (1998). Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. *Journal of Endocrinology*, 156(1), 59-65.
 60. Hillmer, A. M., Hanneken, S., Ritzmann, S., Becker, T., Freudenberg, J., Brockschmidt, F. F., ... & Nöthen, M. M. (2005). Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. *American Journal of Human Genetics*, 77(1), 140-148.
 61. Hillmer, A. M., Brockschmidt, F. F., Hanneken, S., Eigelshoven, S., Stefens, M., Flaquer, A., ... & Nöthen, M. M. (2008). Susceptibility variants for male-pattern baldness at chromosome 20p11. *Nature Genetics*, 40(11), 1279-1281.
 62. Hillmann, K., & Hoffmann, R. (2016). Alopecia areata: evidence-based treatments. *Dermatologic Therapy*, 29(6), 389-398.
 63. Hoffmann, R. (2023). Hormonal regulation of hair growth and loss in men and women. *International Journal of Trichology*, 15(2), 45-52.
 64. Hoffmann, R., Niiyama, S., & Huth, A. (2000). 5 α -reductase activity in pubic skin from patients with male pattern baldness. *Journal of Investigative Dermatology*, 114(4), 734-738.
 65. Imperato-McGinley, J., Guerrero, L., Gautier, T., & Peterson, R. E. (1974). Steroid 5 α -reductase deficiency in man: an inherited form of male pseudohermaphroditism. *Science*, 186(4170), 1213-1215.
 66. Inui, S., Fukuzato, Y., Nakajima, T., Yoshikawa, K., & Itami, S. (2003). Androgen-inducible TGF- β 1 from balding dermal papilla cells inhibits epithelial cell growth. *Journal of Investigative Dermatology*, 121(1), 36-42.
 67. Inui, S., Nakajima, T., Itami, S. Scalp dermoscopy of androgenetic alopecia in Asian people. *J Dermatol*. 2009;36(2):82-85.
 68. Itami, S., Kurata, S., Takayasu, S. 5 alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. *J Invest Dermatol*. 1990;94(2):150-152.
 69. Jaworsky, C., Kligman, A. M., & Murphy, G. F. (1992). Characterization of inflammatory infiltrates in male pattern alopecia. *British Journal of Dermatology*, 127(3), 239-246.
 70. Kantor, J., Kessler, L. J., Brooks, D. G., Cotsarelis, G. Decreased serum ferritin is associated with alopecia in women. *J Invest Dermatol*. 2003;121(5):985-988.
 71. Kaufman, K. D., Olsen, E. A., Whiting, D., Savin, R., DeVillez, R., Bergfeld, W., ... & Hordinsky, M. (1998). Finasteride in the treatment of men with androgenetic alopecia. *Journal of the American Academy of Dermatology*, 39(4), 578-589.



- MANUSCRIPT ID: BTS0826006**
72. Kaufman, K. D., Girman, C. J., Round, E. M., Johnson-Levonas, A. O., Shah, A. K., & Rotonda, J. (2023). Progression of hair loss in men with androgenetic alopecia: a 5-year prospective study. *Journal of the American Academy of Dermatology*, 68(3), 445-451.
 73. Kessels, A. G., Cardynaals, R. L., Borger, R. L., et al. The effectiveness of the hair-pull test in 47 women with androgenetic alopecia. *J Am Acad Dermatol*. 1991;24(4):648-650.
 74. Kiddy, D. S., Sharp, P. S., White, D. M., et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. *Clin Endocrinol (Oxf)*. 1990;32(2):213-220.
 75. Klemp, P., & Peters, K. (1983). Scalp blood flow in androgenetic alopecia. *British Journal of Dermatology*, 108(1), 63-67.
 76. Kligman, A. M. Pathologic dynamics of human hair loss. I. Telogen effluvium. *Arch Dermatol*. 1961;83:175-198.
 77. Konior, R. J., Chernchujit, B., Araki, T., Avram, M., Bartels, N., Bouhanna, P., ... & Yamamoto, A. (2013). Surgical treatment of female pattern hair loss. *Dermatologic Surgery*, 39(1), 1-7.
 78. Kudielka, B. M., & Kirschbaum, C. (2005). Sex differences in HPA axis responses to stress. *Psychoneuroendocrinology*, 30(10), 1033-1043.
 79. Legro, R. S., Castracane, V. D., Kauffman, R. P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. *Obstet Gynecol Surv*. 2004;59(2):141-154.
 80. Li, R., Brockschmidt, F. F., Kiefer, A. K., Stefansson, H., Nyholt, D. R., Song, K., ... & Hinds, D. A. (2012). Six novel susceptibility loci for early-onset androgenetic alopecia and their unexpected association with common diseases. *PLoS Genetics*, 8(5), e1002746.
 81. Liang, T., Hoyer, S., Yu, R., Soltani, K., Lorincz, A. L., Hiipakka, R. A., & Liao, S. (2014). Immunocytochemical localization of androgen receptors in human skin. *Journal of Investigative Dermatology*, 102(4), 465-469.
 82. Lim, X., & Nusse, R. (2013). Wnt signaling in skin development, homeostasis, and disease. *Cold Spring Harbor Perspectives in Biology*, 5(2), a008797.
 83. Lookingbill, D. P., Demers, L. M., Wang, C., Leung, A., Rittmaster, R. S., & Santen, R. J. (1991). Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. *Journal of Clinical Endocrinology & Metabolism*, 72(6), 1242-1248.
 84. Loussouarn, G., El Rawadi, C., & Genain, G. (2005). Diversity of hair growth profiles. *International Journal of Dermatology*, 44(S1), 6-9.
 85. Loussouarn, G., Lozano, I., Panhard, S., Collaudin, C., El Rawadi, C., & Genain, G. (2007). Diversity in human hair growth, diameter, colour and shape. An in vivo study on young adults from 24 countries observed in the five continents. *Eu-*



MANUSCRIPT ID: BTS0826006

- ropean Journal of Dermatology, 17(6), 567-572.
86. Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., ... & Whiting, D. A. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. *Journal of the American Academy of Dermatology*, 50(4), 541-553.
 87. Ludwig, E. (1977). Classification of the types of androgenetic alopecia occurring in the female sex. *British Journal of Dermatology*, 97(3), 247-254.
 88. Lynfield, Y. L. (1960). Effect of pregnancy on the human hair cycle. *Journal of Investigative Dermatology*, 35(6), 323-327.
 89. Magro, C. M., Rossi, A., Poe, J., Manhas-Bhutani, S., & Sadick, N. (2004). The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. *Journal of Drugs in Dermatology*, 3(2), 143-146.
 90. Malkud, S. Telogen effluvium: a review. *J Clin Diagn Res*. 2015;9(9):WE01-WE03.
 91. Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. *British Journal of Dermatology*, 150(2), 186-194.
 92. Messenger, A. G., & Rundegren, J. (2023). Sebaceous gland activity and gender differences in scalp hair loss. *Journal of Investigative Dermatology*, 141(3), 234-241.
 93. Milgraum, S. S., Kunkle, G. A. Postpartum alopecia areata. *J Am Acad Dermatol*. 1988;18(4 Pt 1):799-802.
 94. Milner, Y., Sudnik, J., Filippi, M., Kizoulis, M., Kashgarian, M., & Stenn, K. (2002). Exogen, shedding phase of the hair growth cycle. *Journal of Investigative Dermatology*, 119(3), 639-644.
 95. Mirzoyev, S. A., Schrum, A. G., Davis, M. D., Torgerson, R. R. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. *J Invest Dermatol*. 2014;134(4):1141-1142.
 96. Moltz, L. Hormonal treatment of androgenetic alopecia in women. *J Dtsch Dermatol Ges*. 2003;1(3):181-194.
 97. Morganroth, G. S., Reyes, B. A., Janniger, C. K., et al. Telogen effluvium after anesthesia and surgery. *J Am Acad Dermatol*. 1994;31(6):1035-1037.
 98. Norwood, O. T. (1975). Male pattern baldness: classification and incidence. *Southern Medical Journal*, 68(11), 1359-1365.
 99. Nyholt, D. R., Gillespie, N. A., Heath, A. C., Martin, N. G. Genetic basis of male pattern baldness. *J Invest Dermatol*. 2003;121(6):1561-1564.
 100. Ohnemus, U., Uenalan, M., Inzunza, J., Gustafsson, J. A., & Paus, R. (2005). The hair follicle as an estrogen target and source. *Endocrine Reviews*, 27(6), 677-706.



- MANUSCRIPT ID: BTS0826006**
101. Ohnemus, U., Uenal, M., Conrad, F., Handjiski, B., Mecklenburg, L., Nakamura, M., ... & Paus, R. (2006). Hair cycle control by estrogens: catagen induction via estrogen receptor (ER)- α is checked by ER- β signaling. *Endocrinology*, 147(3), 1268-1276.
 102. Olsen, E. A. (1994). Androgenetic alopecia. In *Disorders of Hair Growth* (pp. 257-283). McGraw-Hill.
 103. Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschien, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. *Journal of the American Academy of Dermatology*, 47(3), 377-385.
 104. Olsen, E. A., Messenger, A. G., Shapiro, J., Bergfeld, W. F., Hordinsky, M. K., Roberts, J. L., ... & Whiting, D. A. (2005). Evaluation and treatment of male and female pattern hair loss. *Journal of the American Academy of Dermatology*, 52(2), 301-311.
 105. Olsen, E. A., Messina, J. L., Plotner, N. A., Shupack, J. L., Stough, D. B., Washenik, K., & Whiting, D. (2005). The importance of dual 5 α -reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *Journal of the American Academy of Dermatology*, 53(6), 1014-1023.
 106. Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., ... & Luo, F. (2006). The importance of dual 5 α -reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. *Journal of the American Academy of Dermatology*, 55(6), 1014-1023.
 107. Oura, H., Iino, M., Nakazawa, Y., Tajima, M., Ideta, R., Nakaya, Y., ... & Arase, S. (2008). Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. *Journal of Dermatology*,